welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Sucampo Enters Into Exclusive Option and Collaboration Agreement With Cancer Prevention Pharmaceuticals for Development of Late-Stage CPP-1X/Sulindac Combination for Familial Adenomatous Polyposis
Sucampo Pharmaceuticals, Inc., a global biopharmaceutical company, today announced an option and collaboration agreement under which Cancer Prevention Pharmaceuticals, Inc. (CPP) has granted Sucampo the sole option to acquire an exclusive license to commercialize CPP-1X/sulindac combination product in North America. This product is currently in a Phase 3 clinical trial for the treatment of familial adenomatous polyposis (FAP).

expertly curated content related to this topic
-
Starch Powder That can be Sprinkled on Food is Tested as Cure for Bowel CancerA powder made from starch that can b...
-
jaime jessenGenetic Counsellor...
-
Familial Investigations of Childhood Cancer PredispositionWhile it is well recognized that heredit...
-
Washtenaw County Man with Rare Genetic Disease Helps Others in Similar SituationImagine the fear and disappointment to l...
-
Robert S. Sandler, MD, MPHNina and John Sessions Distinguished Pro...
-
Familial Adenomatous PolyposisFamilial adenomatous polyposis is an inh...